Zhaoke Ophthalmology Limited has entered into an exclusive distribution and supply agreement with Indonesian pharmaceutical company PT Erlangga Edi Laboratories (PT Erela) to register, import, promote, market and sell CsA Ophthalmic Gel in Indonesia. The agreement provides Zhaoke Ophthalmology with an upfront payment and additional milestone payments contingent on preset achievements.

CsA Ophthalmic Gel is a patented cyclosporine hydrogel under development in China for moderate-to-severe dry eye disease (DED). Leveraging nanomicelle technology, the formulation offers strong muco-adhesion, prolonged corneal residence and improved bioavailability, enabling once-daily nighttime dosing. Phase II results indicated efficacy and safety at least comparable to the twice-daily emulsion Restasis (0.05% CsA), while Phase III data showed onset of action within two weeks, which could enhance patient compliance.

Founded in 1965, PT Erela manufactures more than 150 pharmaceutical, traditional medicine and supplement SKUs. Its distribution network spans over 10,000 pharmacies and major hospital chains across Indonesia, positioning the company to accelerate market penetration of CsA Ophthalmic Gel.

The announcement notes that successful development and commercialization of CsA Ophthalmic Gel remain subject to regulatory and clinical milestones, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.